| Market Capitalization (Millions $) |
554 |
| Shares
Outstanding (Millions) |
86 |
| Employees |
89 |
| Revenues (TTM) (Millions $) |
54 |
| Net Income (TTM) (Millions $) |
-174 |
| Cash Flow (TTM) (Millions $) |
187 |
| Capital Exp. (TTM) (Millions $) |
0 |
Kura Oncology Inc
Kura Oncology Inc is a publicly-traded biopharmaceutical company headquartered in La Jolla, California. The company is focused on developing innovative medicines for the treatment of cancer. Kuraes lead drug candidate, tipifarnib, is a selective farnesyltransferase inhibitor, which inhibits a critical enzyme in the Ras pathway, and has shown promising results in various clinical trials.
The company was founded in 2014 by Troy Wilson and Yi Liu. It raised $60 million in its initial public offering in 2015, and since then has continued to raise additional capital through secondary offerings and collaborations. As of 2021, Kura has a market capitalization of over $1 billion.
Kura is focused on developing drugs that target various cancer indications, particularly those with high unmet medical needs. The companyes pipeline includes several promising drug candidates in various stages of development, including KRA inhibitor, Kura-009, which is in Phase I clinical trials for the treatment of solid tumors with K-Ras mutations, and Menin-MLL inhibitor, KO-539, which is in preclinical development for the treatment of patients with leukemias and several other hematologic malignancies.
The companyes lead drug candidate, tipifarnib, has the potential to be a game-changer in the treatment of hematologic malignancies, particularly in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Tipifarnib has already been granted fast track designation by the FDA, and its ongoing phase II clinical trials are showing promising results. The drug has also shown potential in treating other indications such as advanced head and neck cancer and peripheral T-cell lymphoma.
Kuraes scientific team consists of experts in drug discovery, preclinical evaluation, clinical development, and regulatory affairs. The company has a collaborative approach and works closely with academic institutions, clinical investigators, and industry partners, making it a leading player in the field of oncology drug development.
In summary, Kura Oncology Inc is a fast-growing biopharmaceutical company that is committed to developing innovative drugs for the treatment of cancer, particularly hematologic malignancies. The companyes pipeline of drug candidates, led by the promising tipifarnib, has the potential to revolutionize cancer treatment and improve the lives of patients suffering from cancer.
Company Address: 12730 High Bluff Drive San Diego 92130 CA
Company Phone Number: 500-8800 Stock Exchange / Ticker: NASDAQ KURA
|
0.000%
9.07%